



October 10, 2018

Provider News

New Hepatitis B Vaccine for Adults

Heplisav-B (HepB-CpG) was licensed in 2017 by the FDA and subsequently recommended by the Advisory Committee on Immunization Practices for persons 18 years of age and older. The vaccine has been added as an Alliance benefit as of October 1, 2018. The Heplisav-B vaccine series can be completed in two doses with at least one month between the doses. Vaccine is the primary means for preventing hepatitis B virus infection and its complications. For more information about hepatitis B vaccine and recommendations for use, please see the full guidance from the Centers for Disease Control and Prevention (CDC) at www.cdc.gov/mmwr/volumes/67/wr/mm6715a5.htm.